Tirzepatide
Tirzepatide is a lab-made peptide that switches on two gut-hormone receptors, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). It is studied in people for weight management and blood sugar control, including in the SURPASS and SURMOUNT trial programs.
At a glance
- TRZ
- Metabolic support
- subcutaneous
- Observational humanObservational human, across 1 audit
- 5 mg per Peptide Dosing Protocols. All 4 sources
- 40 mg in 2 mL
How much to draw
Full calculator →Opened on 5 mg, the figure Peptide Dosing Protocols reports for Tirzepatide, and a 40 mg vial in 2 mL. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Tirzepatide or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Standard: 5 mg once weekly · Low: 2.5 mg once weekly · High: 15 mg once weekly | once weeklyCycle length Planning note 4 weeks (Phase 1, 2. | Subcutaneous injection | Peptide Dosing ProtocolsWhat it saysHideHalf-life: 5 days. Tirzepatide is administered once weekly, starting at 5 mg. |
| 2.5 mg starting dose, escalating to 5-15 mg maintenance | Once weeklyOngoing (chronic therapy) | subcutaneous or oral | Peptide Protocol Wiki |
| Standard: 5 mg, 10 mg, or 15 mg once weekly (three approved maintenance doses) · Low: 2.5 mg once weekly · High: 15 mg once weekly | Once weeklyWeeks 1-4 at 2.5 mg, stepping up every 4 weeks; full ladder to 15 mg reached at week 21+ · 4 weeks (Phase 1, 2.5 mg), 8 weeks (through 5 mg), 12 weeks (through 7.5 mg), 16 weeks (through 10 mg), 24 weeks (full ladder to 15 mg) | Subcutaneous injection | Peptide Dosing ProtocolsWhat it saysHideHalf-life: 5 days. Tirzepatide is titrated once weekly from 2.5 mg up to a maximum of 15 mg in 2.5 mg increments every 4 weeks via subcutaneous injection. |
| 2.5-15 mg | Once weekly · Any time of dayTitrate over weeks per response/tolerance | subcutaneous | Reference titration range, provider confirm |
- once weeklyCycle length Planning note 4 weeks (Phase 1, 2.
- Subcutaneous injection
- Peptide Dosing Protocols
What it saysHide
Half-life: 5 days. Tirzepatide is administered once weekly, starting at 5 mg.
- Once weeklyOngoing (chronic therapy)
- subcutaneous or oral
- Peptide Protocol Wiki
- Once weeklyWeeks 1-4 at 2.5 mg, stepping up every 4 weeks; full ladder to 15 mg reached at week 21+ · 4 weeks (Phase 1, 2.5 mg), 8 weeks (through 5 mg), 12 weeks (through 7.5 mg), 16 weeks (through 10 mg), 24 weeks (full ladder to 15 mg)
- Subcutaneous injection
- Peptide Dosing Protocols
What it saysHide
Half-life: 5 days. Tirzepatide is titrated once weekly from 2.5 mg up to a maximum of 15 mg in 2.5 mg increments every 4 weeks via subcutaneous injection.
- Once weekly · Any time of dayTitrate over weeks per response/tolerance
- subcutaneous
- Reference titration range, provider confirm
- 2.0 mL BAC water for a 40 mg vial
- 40 mg vial + 2.0 mL BAC water = 20 mg/mL; reconstituted solution keeps for ~28 days refrigerated
Tirzepatide "Prevents Diabetes." Prevented, Delayed, or Masked?
The prevention result is one of the stronger things in the incretin literature, and the screenshot version of it can't answer any of the three questions that would make it usable.
How it is thought to work
Tirzepatide appears to help the body release insulin when blood sugar is high, lower the hormone glucagon, slow how fast the stomach empties and reduce appetite in some patients. Researchers link this to its action as a dual agonist, meaning it activates both the GIP and GLP-1 receptors, which respond to gut hormones after meals. How much the GIP side adds to clinical results is still an active research topic.
Activates GIP and GLP-1 receptors, reducing appetite, slowing gastric emptying, and improving insulin response.
What we don't know
Diabetes prevention after stopping: our audit says the trial result covers crossing the diabetes diagnostic threshold while treatment continued. It treats what happens after the drug is stopped as the question that decides whether diabetes was prevented, delayed or masked.
Who the result applies to: the prevention finding comes from higher-BMI adults with prediabetes. The audit says carrying it over to people with normal glucose tolerance is not supported.
Against semaglutide: there is no head-to-head trial of tirzepatide against semaglutide on a diabetes-prevention endpoint.
Thyroid tumours and the GIP receptor: rodent studies showed thyroid C-cell tumours, and what that means for humans is uncertain. How much the GIP receptor adds to clinical outcomes remains an active research topic.
Reported side effects
Seen in studies: most effects are digestive and were usually worst while the dose was going up. Across the SURPASS and SURMOUNT trials, nausea was reported in roughly 17-22% of participants, diarrhea in 13-16%, vomiting in 6-10%, lower appetite in 7-9% and indigestion in about 7%. Injection-site reactions were reported in about 3-7%, and resting heart rate rose by 2-4 bpm. A meta-analysis of 10 trials (6,836 participants) found digestive events in 39% at 5 mg, 46% at 10 mg and 49% at 15 mg. About 5% stopped because of side effects at 5 mg and about 10% at 15 mg. Acute pancreatitis, gallstones and gallbladder inflammation have been reported, as has kidney injury after dehydration from severe vomiting. Low blood sugar is rare on tirzepatide alone, but the risk rises sharply with insulin or sulfonylureas.
Not ruled out: thyroid C-cell tumors. Rodent studies showed these tumors rising with dose, and what that means for humans is uncertain. This is the subject of a boxed warning.
Who should avoid it
People with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2: rodent studies showed thyroid C-cell tumors, and the label carries a boxed warning and a contraindication for this group.
People with a history of pancreatitis: pancreatitis has been reported with tirzepatide.
Pregnant people: animal data show possible harm to the fetus. The source describes stopping at least 2 months before a planned pregnancy because the drug stays in the body a long time.
People with severe gut disease, such as gastroparesis or severe IBD: tirzepatide slows stomach emptying, which may make existing symptoms worse.
People with type 1 diabetes: it is not a substitute for insulin and is not approved for type 1 diabetes or diabetic ketoacidosis.
Children and adolescents under 18: safety and effectiveness have not been established outside of trials.
People using oral contraceptives: slower stomach emptying can reduce how much of the pill is absorbed. The source describes backup contraception for the first 4 weeks and after every dose increase.
What gets monitored
Weight/body-composition trend, glucose/HbA1c, GI tolerance per provider.
Regulatory status
FDA approval: tirzepatide is FDA-approved under two brand names. Mounjaro was approved in May 2022 for type 2 diabetes. Zepbound was approved in November 2023 for chronic weight management and in December 2024 for moderate-to-severe obstructive sleep apnea with obesity.
Label limits: the label carries a boxed warning about thyroid C-cell tumours seen in rodent studies. Tirzepatide is not approved for type 1 diabetes, and safety and effectiveness in people under 18 have not been established outside trials.
Checked: November 2026.
Common questions
What is the starting dose of tirzepatide?
Sources that report a dose describe 2.5 mg once weekly by subcutaneous injection for the first 4 weeks, which they call a tolerability step and not a treatment dose. They then describe a move to 5 mg, with further steps of 2.5 mg at least 4 weeks apart, up to 15 mg weekly depending on individual tolerance.
What is the highest dose of tirzepatide / Zepbound?
The maximum FDA-approved dose is 15 mg once weekly for both Mounjaro and Zepbound. In SURMOUNT-1 the 15 mg group averaged 22.5% body weight loss at 72 weeks, only modestly more than the 21.4% seen in the 10 mg group.
What is tirzepatide's half-life?
Its half-life is approximately 5 days, or about 120 hours. With weekly injections, blood levels build over about 4 weeks before settling at roughly 1.6 times a single dose. The source gives this as the reason each dose step lasts at least 4 weeks.
How do you convert tirzepatide mg to insulin units?
That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.
How much weight can you lose on tirzepatide?
In SURMOUNT-1, average body weight loss at 72 weeks was 22.5% in the 15 mg group, 21.4% in the 10 mg group and 16.0% in the 5 mg group. In SURMOUNT-5, tirzepatide produced 20.2% weight loss against 13.7% for semaglutide. These are averages across trial populations, not promises for any individual.
How do you reconstitute tirzepatide?
That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.
Is tirzepatide FDA-approved?
Yes. Mounjaro was FDA-approved in May 2022 for type 2 diabetes. Zepbound was approved in November 2023 for chronic weight management and in December 2024 for moderate-to-severe obstructive sleep apnea with obesity.
What is the difference between Mounjaro and Zepbound?
Both contain the same active drug, tirzepatide, on the same dose steps. The differences are the labeled use and the packaging. Mounjaro is labeled for type 2 diabetes, and Zepbound for chronic weight management and obstructive sleep apnea with obesity.
Sources
- 01Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine (2022)
- 02Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine (2025)
- 03Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine (2021)
- 04Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet (2021)
- 05Dahl D, Onishi Y, Norwood P, et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (SURPASS-5). JAMA (2022)
- 06Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT). New England Journal of Medicine (2024)
- 07Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). New England Journal of Medicine (2024)
- 08U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection — Prescribing Information and Approval History. FDA Drug Approvals (2022)
- 09U.S. Food and Drug Administration. Zepbound (tirzepatide) injection — Prescribing Information and Approval History. FDA Drug Approvals (2023)
- 10Sinha R, Papamargaritis D, Sargeant JA, Davies MJ. Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management (meta-analysis of SURPASS). Journal of Obesity & Metabolic Syndrome (2023)
- 11Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism (2018)
- 12ClinicalTrials.gov. A Study of Tirzepatide (LY3298176) on Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT, NCT04255433). ClinicalTrials.gov (2026)
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
Cagrilintide / Retatrutide is a combination of cagrilintide, an amylin analog, and retatrutide, a triple GLP-1, GIP and glucagon agonist, sold pre-blended in one vial or as separate vials. It is discussed for weight management, and no clinical trial has tested the two together.
Cagrilintide / Tirzepatide is a combination of cagrilintide, an amylin analog, and tirzepatide, a dual GIP and GLP-1 agonist, each given once weekly from its own vial. It is discussed for weight management, with one study in obese rats and no human trial of the two together.
CagriSema is an investigational fixed-dose combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist, given once weekly. It has been studied for weight management in people in Phase 3 trials and is not FDA-approved as of June 2026.
Mazdutide, also called IBI362, is an investigational lab-made peptide drug that switches on two metabolic hormone receptors at once. It is being studied in clinical trials as a once-weekly injection for weight management and metabolic health.
Retatrutide is an investigational once-weekly injectable that acts on three hormone receptors at once: GLP-1, GIP and glucagon. It is being studied for weight and metabolic outcomes in adults with obesity, type 2 diabetes and fatty liver disease.
Semaglutide is a lab-made copy of GLP-1, a gut hormone that helps the body manage hunger and blood sugar. It is among the most heavily studied weight-loss and diabetes medicines, with trial programmes covering more than 45,000 participants.